Check your eligibility now & get in touch with a study center

CHECK ELIGIBILITY

REDUCE Study: For patients with Elevated Left Atrial Pressure with Heart Failure

This study is assessing the safety and tolerability of an interatrial septal device implanted for those who have a dilated left atrium or some degree of diastolic dysfunction. This is often known as preserved ejection fraction heart failure. This study is blinded over the course of 2 years, and there is a crossover period at the end for those who still meet criteria and who were in the control group.
Am I eligible? Learn More

Detailed Description

Clinic visits involve physical exam, blood work, EKG, 6 minute walk test, and questionnaires. 

Visits:
Screening visit in clinic
Randomization and procedure date (this would include a right heart catheterization and exercise bike, to assess hemodynamics at peak exercise)

Follow up clinic visits:
1 month 
3 month
6 month
12 month
24 month
every year after that

Call 1800-9860-568 now to find out if you are eligible.

Age

40 - 100

Gender

All

NCT ID

NCT03088033

Phase

3

Status

Recruiting Now

Medical Condition

Atrial Fibrillation

Your Journey

01
Receiving the medication

You would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.

02
Visiting the study site

Study participation involves approximately 8 visits to your local study center over 6 to 7 months.

03
Follow-up

There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.

Call 1800-789-7366 now to find out if you are eligible.